Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26 - PRAX News | RalliesPraxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26
P
PRAX• Regulatory update
- FDA mid-cycle reviews flagged no major safety or efficacy issues for ulixacaltamide (PDUFA Jan. 29, 2027) or relutrigine (PDUFA Dec. 27, 2026).
Q2 financial results
- Praxis Precision Medicines posted a Q2 GAAP net loss of USD 83.7 million, widening from USD 71.1 million a year earlier.
- R&D expenses rose 10.16% to USD 69.4 million, driven by higher Solidus spending and personnel costs, partly offset by lower Cerebrum expenses.
- G&A costs more than doubled to USD 27.5 million, on higher professional fees and personnel-related expenses.
- Cash, cash equivalents and marketable securities totaled USD 1.4 billion at June 30, extending the expected operating runway into 2028.
